Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +34.35%
#2 Siren Siren +31.73%
#3 OriginTrail OriginTrail +18.20%
#4 Purr Purr +17.28%
#5 龙虾 (Lobster) 龙虾 (Lobster) +12.28%
#6 Ethena Staked ENA Ethena Staked ENA +11.62%
#7 Wrapped XPL Wrapped XPL +11.23%
#8 DigiByte DigiByte +11.00%
#9 Collect on Fanable Collect on Fanable +10.98%
#10 Plasma Plasma +10.85%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

PRTK
Classement en actions #21736
Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in... Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.
Prix de l'action
$2.23
Dernière synchronisation: 2023-09-29
Capitalisation boursière
$101.43M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Paratek Pharmaceuticals, Inc. (PRTK)

Catégorie

Healthcare
Le prix PRTK avec la capitalisation boursière de B
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
PRTK
$2.23
Capitalisation boursière de Paratek Pharmaceuticals, Inc.(PRTK)
Capitalisation boursière: $101.43M
En August 2026, Paratek Pharmaceuticals, Inc. a une capitalisation boursière de $101.43M. Cela fait de Paratek Pharmaceuticals, Inc. la 21736th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Paratek Pharmaceuticals, Inc. du 2009 au 2026
PRTK par rapport au top 5 des plus populaires stocks
Prix pour PRTK L’actif B La capitalisation boursière de B Résultats
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$114,578 $101.43M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +5,137,926.54%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$99,965.49 $101.43M
Apple Inc. Apple Inc.
AAPL
$4.547T +4,482,657.23%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$91,516.86 $101.43M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +4,103,795.24%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$78,991.67 $101.43M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,542,127.48%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$61,404.14 $101.43M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,753,449.00%